Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Eli Lilly's stock price rise of 9% YTD might ... The most concerning of the potential drags on LLY were its recent legal issues. The company had just sued the government's Health Resources and ...

Current health news covers major investments by Merck Animal Health and Gilead Sciences in the U.S., regulatory decisions ...

Eli Lilly has filed lawsuits ... solutions for individual patient needs. The legal action also questions the safety of the compounded drugs and challenges whether the defendants are violating ...

US President Donald Trump signed an executive order requiring drugmakers to lower prices, aligning with international rates.

Bristol-Myers Squibb has become the latest drugmaker in the US to file a legal challenge to a block ... rebate model from Johnson & Johnson and Eli Lilly. In calendar 2023, around $66.3 billion ...

Eli Lilly is escalating its legal push to protect the exclusivity ... Novo Nordisk, the maker of Wegovy and Ozempic, may soon face a similar challenge, as compounded versions of its own obesity ...

Eli Lilly (NYSE:LLY ... is also over. Earlier in April, Lilly took legal action against two compounding pharmacies seeking to stop them from manufacturing and marketing compounded tirzepatide.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...